This vaccine is authorized for use for those aged 6 months and above, with an adjustment in the recommended dosage in those aged 6 months – 4 years, and those aged 5-11 years.
WHO recommends that countries should consider using the vaccine in children aged 6 months to 17 years only when high vaccine coverage with 2 doses has been achieved in the high priority groups as identified in the WHO Prioritization Roadmap.
Children and adolescents aged 6 months to 17 years of age with comorbidities that put them at significantly higher risk of serious COVID-19 disease, should be offered vaccination, alongside other high-risk groups.
8325
关于疫苗在12岁以下儿童中的安全性和有效性的研究仍在进行中。
Studies on the safety and efficacy of the vaccine in children aged below 12 are still ongoing.
In accordance with the WHO Prioritization Roadmap, the priority remains to prevent deaths by achieving high vaccine coverage (primary series and boosters) in the highest and high priority-use groups.
8327
一般而言，儿童面临的COVID-19风险较低。
In general, children are at lower risk of COVID-19.
8328
这就是为什么世卫组织建议各国优先为高风险人群接种疫苗。
That is why WHO recommends that countries prioritize vaccinating people who have higher risk first.
8329
这种疫苗安全吗？
Is it safe?
8330
2021年4月30日，世卫组织将莫德纳疫苗列入紧急使用列表。
On 30 April 2021, WHO listed the Moderna vaccine for emergency use.